Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis
NCT00615173 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 81
Last updated 2008-10-29
Summary
The purpose of this study is to compare the efficacy and safety of tacrolimus vs intravenous cyclophosphamide pulses treatment for the induction therapy of LN(III,IV,V).
To compare the efficacy and safety of tacrolimus vs Azathioprine for the maintenance therapy of LN(III,IV,V).
Conditions
- Kidney Diseases
- Lupus Nephritis
- Tacrolimus
- Induction Phase
- Maintenance Phase
Interventions
- DRUG
-
tacrolimus (FK506)
Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
- DRUG
-
cyclophosphamide or azathioprine
Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Principal Investigators
-
Xue Qing Yu, MD · Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University
-
Ping Fu, MD · Department of Nephrology, West China Hospital of Sichuan University
-
Yun Hua Liao, MD · Department of Nephrology, 1st Affiliated Hospital of Guangxi Medical University
-
Jin li Zhang, MD · Department of nephrology, People's Hospital of Yunnan Province
-
Jian Chen, MD · Department of Nephrology, Fuzhou Military General Hospital
-
Tan Qi Lou, MD · Department of Nephrology, 3rd Affiliated Hospital of Sun Yet-Sen University
-
Yao zhong Kong, MD · Department of Nephrology, 1st People's Hospital of Foshan
-
Jun zhou Fu, MD · Department of Nephrology,1st People's Hospital of Guangzhou
-
Wei Shi, MD · Department of Nephrology, People's Hospital Guangdong Provincial
-
Zheng rong Liu, MD · Department of Nephrology, Nanfang Hospital of Southern Medical University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 14 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-07-31
- Primary Completion
- 2008-09-30
- Completion
- 2008-09-30
Countries
- China
Study Locations
More Related Trials
-
Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study
NCT00429377 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
NCT00298506 ·Status: COMPLETED ·Phase: NA
-
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients
NCT01342016 ·Status: TERMINATED ·Phase: PHASE3
-
Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
NCT00371319 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
NCT00404794 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
NCT00569101 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
NCT01580865 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
NCT05916781 ·Status: RECRUITING ·Phase: PHASE4
-
Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis
NCT01203709 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis
NCT01328834 ·Status: COMPLETED ·Phase: PHASE3
-
Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone
NCT00268567 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis
NCT01056237 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis
NCT01288664 ·Status: WITHDRAWN ·Phase: PHASE3
-
Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
NCT01060410 ·Status: COMPLETED
-
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174 ·Status: RECRUITING
-
Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
NCT01206569 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
NCT02954939 ·Status: RECRUITING ·Phase: NA
-
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
NCT07077486 ·Status: RECRUITING ·Phase: PHASE4
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289 ·Status: RECRUITING ·Phase: PHASE2
-
To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis
NCT00881309 ·Status: COMPLETED ·Phase: NA
-
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192 ·Status: COMPLETED ·Phase: PHASE2
-
Drug Therapy in Lupus Nephropathy
NCT00001212 ·Status: COMPLETED ·Phase: PHASE2
-
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
NCT01172002 ·Status: UNKNOWN ·Phase: NA
-
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis
NCT03200002 ·Status: COMPLETED ·Phase: PHASE2